Assess whether to resubmit, meet, or pause the program (6070bb)

SITUATION Regulatory-affairs lead owns this Clinical and Evidence Strategy review in a labeling team facing a boxed-warning debate. A CMO 483 that maps to the NDA CMC module is the triggering event; disproportionate reporting signal workbook is the evidence for whether to resubmit, meet, or pause the program.

DECISION Regulatory-affairs lead in a labeling team facing a boxed-warning debate must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. The population in disproportionate reporting signal workbook is the one a CMO 483 that maps to the NDA CMC module named, so To resubmit, meet, follows for this Clinical and Evidence Strategy file. 2. The population in disproportionate reporting signal workbook is adjacent only to a CMO 483 that maps to the NDA CMC module; Pause the program is the honest Pharma & Life Sciences call. 3. A labeling team facing a boxed-warning debate already contained a CMO 483 that maps to the NDA CMC module before disproportionate reporting signal workbook arrived; no new Clinical and Evidence Strategy path. 4. Provenance on disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Check whether disproportionate reporting signal workbook supports the labeled claim regulatory-affairs lead would keep. 2. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 3. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for regulatory-affairs lead in a labeling team facing a boxed-warning debate.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in disproportionate reporting signal workbook, then the action for regulatory-affairs lead - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Regulatory or exam hook Clinical and Evidence Strategy would cite - Clinical and Evidence Strategy finding in disproportionate reporting signal workbook that a second reviewer can re-perform